Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06959888 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Study in Healthy Volunteers to Evaluate the Relative Bioavailability of ALG-055009 Formulations
A Phase 1 study of Healthy Volunteer Study, sponsored by Aligos Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
- 1
- Study location
NCT06959888: Completed Phase 1 study of Healthy Volunteer Study, sponsored by Aligos Therapeutics.
NCT06959888 is a Phase 1 study of Healthy Volunteer Study that has completed, run by Aligos Therapeutics. The registered enrollment target is 8 participants, below the 36-participant average among 9 other Healthy Volunteer Study trials with a reported enrollment target (78% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06959888, a Phase 1 study of Healthy Volunteer Study, has completed, sponsored by Aligos Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a phase 1 single dose, open-label, randomized, two-period, two-sequence, crossover study of ALG-055009 conducted in 1 cohort of healthy volunteers. The primary purpose of this study is to compare the single-dose pharmacokinetics of the 0.7 mg dose level of 2 types of soft gelatin capsule formulations of ALG-055009, Formulation 1 and Formulation 2, in approximately 8 healthy volunteers.
Primary Outcome
AUC0-24, of ALG-055009 in plasma following single dose administration of 0.7 mg ALG-055009 Formulation 1 and Formulation 2
Conditions Studied
Interventions
- DRUG ALG-055009
Study Locations (1)
Texas
- PPD Austin CRU - Austin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2025-03-25 |
| Est. Completion | 2025-05-16 |
| Phase | Phase 1 |
What the finished NCT06959888 record still lists
NCT06959888 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 36-participant average among 9 other Healthy Volunteer Study trials with a reported enrollment target (78% lower).
The record links to 1 condition, with Healthy Volunteer Study appearing as the primary indexed condition, and to 1 intervention - of which ALG-055009 is the first listed.
NCT06959888 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT06959888 about?
NCT06959888 is a clinical study titled "A Phase 1 Study in Healthy Volunteers to Evaluate the Relative Bioavailability of ALG-055009 Formulations". This is a phase 1 single dose, open-label, randomized, two-period, two-sequence, crossover study of ALG-055009 conducted in 1 cohort of healthy volunteers. The primary purpose of this study is to compare the single-dose pharmacokinetics of the 0.7 mg dose level of 2 types of soft gelatin capsule for...
What is the current status of trial NCT06959888?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2025-03-25. Estimated completion is 2025-05-16.
What conditions does trial NCT06959888 study?
This clinical trial studies the following conditions: Healthy Volunteer Study.
What interventions are being tested in trial NCT06959888?
The interventions under investigation include: ALG-055009 (DRUG).
Who is sponsoring clinical trial NCT06959888?
This trial is sponsored by Aligos Therapeutics, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06959888 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy Volunteer Study
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06959888's enrollment target sits among peer trials
8 9th of 9 higher than 1 of 9 other Healthy Volunteer Study trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Healthy Volunteer Study trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of Bemnifosbuvir/Ruzasvir as a Fixed-dose Combination in Subjects With Normal or Severely Impaired Renal or Hepatic Function
RECRUITING · Phase 1
-
Exploratory Clinical Study to Assess Safety and Efficacy of Xenon Gas Inhalation to Control Neuroinflammation
RECRUITING · Phase 1
-
A Pharmacokinetic Study of Intravenous and Intranasal Oxytocin in Healthy Subjects
COMPLETED · Phase 1
-
Study of Intranasal Octreotide (DP1038) in Healthy Adult Volunteers
COMPLETED · Phase 1
-
Mass Balance Study of AT-527 in Healthy Adult Male Subjects (R07496998)
COMPLETED · Phase 1
-
Near-InfraRed Spectroscopy of Auricular Stimulation
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI